MAIA Biotechnology (NYSEAMERICAN:MAIA) Announces Earnings Results

MAIA Biotechnology (NYSEAMERICAN:MAIA) announced its quarterly earnings data on Tuesday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.21, Zacks reports.

MAIA Biotechnology Price Performance

NYSEAMERICAN:MAIA traded down $0.20 during trading hours on Thursday, reaching $2.19. The stock had a trading volume of 128,765 shares, compared to its average volume of 286,300. The company has a market cap of $52.36 million, a price-to-earnings ratio of -1.57 and a beta of 0.32. MAIA Biotechnology has a 52 week low of $0.82 and a 52 week high of $5.99.

Insider Buying and Selling

In other MAIA Biotechnology news, Director Cristian Luput purchased 22,133 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was purchased at an average price of $2.51 per share, with a total value of $55,553.83. Following the acquisition, the director now owns 389,483 shares in the company, valued at approximately $977,602.33. The trade was a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 36.98% of the stock is currently owned by company insiders.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.